COVID-19 has fundamentally altered the drug development landscape in ways that are both transformational and far-reaching. From the integration of powerful technologies to assist with the discovery and development of promising new drug candidates, to the adoption of novel, decentralized clinical trial designs, which reduce the burden on patients participating in clinical studies, the drug development enterprise has met the challenge of COVID-19, and is embracing new operational and business models to maximize productivity and ROI going forward.